Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 10/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 10/20 | 0.60 |
| ▸ | RELA | Q04206 | 10/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986242 | 0.84 | ROCK2 (0.69) | NFKB1NFKB2RELAROCK2AKT1 | |
| SCHEMBL1988576 | 0.83 | ROCK2 (0.59) | NFKB1NFKB2RELAROCK2AKT1 | |
| SCHEMBL1987178 | 0.82 | ROCK2 (0.69) | NFKB1NFKB2RELAROCK2AKT1 | |
| SCHEMBL24193393 | 0.74 | NFKB1 (0.56) | NFKB1NFKB2RELAMAPTSMN1; SMN2 | |
| SCHEMBL1987882 | 0.72 | ROCK2 (0.79) | ROCK2AKT1RAB9ALMNANPC1 | |
| SCHEMBL1986233 | 0.71 | ROCK2 (1.00) | ROCK2AKT1RAB9ALMNANPC1 | |
| SCHEMBL1988406 | 0.71 | ROCK2 (1.00) | ROCK2AKT1RAB9ALMNANPC1 | |
| SCHEMBL4522482 | 0.66 | MAPT (0.50) | ROCK2AKT1RAB9ALMNANPC1 | |
| SCHEMBL4524945 | 0.66 | HDAC8 (0.53) | ROCK2AKT1ROCK1MEN1KMT2A | |
| SCHEMBL4522235 | 0.66 | HDAC8 (0.53) | ROCK2AKT1ROCK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2009079008-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | FENG YANGBO (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, RHOA, RHOT2 | NFKB1 2921/4885NFKB2 2904/4885RELA 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.